BeiGene, a global biotechnology company, announced that the U.S. FDA  has approved its Bruton’s tyrosine kinase inhibitor (BTKi) BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). “With four US approvals in just over three years and demonstrated superiority versus ibrutinib in the final progression-free survival […]

The post BeiGene’s Brukinsa receives UK marketing authorisations to treat cancers first appeared on World Pharma Today.